Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Apr 1:131:93-98.
doi: 10.1016/j.ejps.2019.02.013. Epub 2019 Feb 10.

Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies

Mohamed H Solayman  1 , Taimour Y Langaee  2 , Yan Gong  2 , Mohamed H Shahin  2 , Stephen T Turner  3 , Arlene B Chapman  4 , John G Gums  5 , Eric Boerwinkle  6 , Amber L Beitelshees  7 , Manal El-Hamamsy  8 , Lamia El-Wakeel  8 , Rhonda M Cooper-DeHoff  2 , Osama A Badary  8 , Julie A Johnson  9
Affiliations
Randomized Controlled Trial

Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies

Mohamed H Solayman et al. Eur J Pharm Sci. .

Abstract

β-blockers show variable efficacy as antihypertensives. Herein, we evaluated plasma miRNAs as biomarkers for defining antihypertensive response to β-blockers. Expression of 22 β-blocker pharmacodynamics-related miRNAs was assessed in baseline plasma samples from 30 responders and 30 non-responders to metoprolol from the PEAR-2 study (Discovery). Logistic regression was performed to identify miRNAs significantly associated with metoprolol response. Those miRNAs were profiled in baseline plasma samples from 25 responders and 25 non-responders to atenolol from the PEAR study (validation). In discovery, miR-101, miR-27a, miR-22, miR-19a, and let-7e were significantly associated with metoprolol response (P = 0.01, 0.017, 0.025, 0.025, and 0.04, respectively). In validation, miR-19a was significantly associated with atenolol response (P = 0.038). Meta-analysis between PEAR-2 and PEAR revealed significant association between miR-19a (P = 0.004), miR-101 (P = 0.006), and let-7e (P = 0.012) and β-blocker response. Hence, miR-19a, miR-101, and let-7e, which regulate β1-adrenergic receptor and other β-blocker pharmacodynamics-related genes, may be biomarkers for antihypertensive response to β-blockers.

Keywords: Antihypertensive response; Beta-blocker; Biomarker; Hypertension; microRNA.

PubMed Disclaimer

Conflict of interest statement

Disclosures

The authors declared no conflict of interest.

Figures

Fig. 1.
Fig. 1.
A flow chart representing study design. miRNAs that were significantly differentially expressed between responders and non-responders in the discovery phase were included in the validation phase. BP: Blood Pressure; PEAR-2: Pharmacogenomic Evaluation of Antihypertensive Responses-2 clinical trial; PEAR: Pharmacogenomic Evaluation of Antihypertensive Responses clinical trial; qRT-PCR: Quantitative Reverse Transcription Polymerase Chain reaction.
Fig. 2.
Fig. 2.
Relative expression of the microRNAs that showed the same direction of differential expression in both in the discovery phase and the validation phase. Bar chart represents the fold change of the differentially expressed miRNA (miR-19a, miR-101, and let-7e) between responders (R) and non-responders (NR) to the antihypertensive effect of the β-blocker metoprolol in the discovery phase and atenolol in the validation phase. Numbers represent P-value of Mann-Whitney U test.
See this image and copyright information in PMC

References

    1. Chen X, et al. , 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18, 997–1006. - PubMed
    1. Chen Q, et al. , 2013. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac. J. Cancer Prev 14, 7421–7426. - PubMed
    1. Egan BM, et al. , 2010. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303, 2043–2050. - PubMed
    1. Farh KK, et al. , 2005. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310, 1817–1821. - PubMed
    1. Friedman RC, et al. , 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105. - PMC - PubMed

Publication types